Provider: NIHR Journals Library
Content:text/plain; charset="UTF-8"
TY  - JOUR
LB  - 1.
AU  - Zaninotto, P
AU  - Head, J
AU  - Stamatakis, E
AU  - Wardle, H
AU  - Mindell, J
TI  - Trends in obesity among adults in England from 1993 to 2004 by age and social class and projections of prevalence to 2012
J2  - J Epidemiol Community Health
PY  - 2009
VL  - 63
SP  - 140
EP  - 146
ER  - 
TY  - JOUR
LB  - 2.
AU  - Morrell, J
AU  - Fox, KA
TI  - Prevalence of abdominal obesity in primary care: the IDEA UK study
J2  - Int J Clin Pract
PY  - 2009
VL  - 63
SP  - 1301
EP  - 1307
ER  - 
TY  - BOOK
LB  - 3.
AU  - McPherson, K
AU  - Marsh, T
AU  - Brown, M
TI  - Modelling future trends in obesity and the impact on health
CY  - Foresight Tackling Obesities
PB  - Future Choices
PY  - 2007
UR  - www.foresight.gov.uk
Y2  - January 2010
ER  - 
TY  - ELEC
LB  - 4.
AU  - National Obesity Observatory
UR  - www.noo.org.uk
M1  - January 2010
ER  - 
TY  - ELEC
LB  - 5.
AU  - World Health Organization Global Infobase
TI  - Obesity and overweight fact sheet September 2006
UR  - www.who.int
M1  - 1 February 2010
ER  - 
TY  - ELEC
LB  - 6.
AU  - NHS
TI  - Statistics on obesity, physical activity and diet: England
UR  - www.ic.nhs.uk/
M1  - January 2010
ER  - 
TY  - JOUR
LB  - 7.
AU  - Guillaume, M
AU  - Lapidus, L
AU  - Beckers, F
AU  - Lambert, A
AU  - Bjorntorp, P
TI  - Familial trends of obesity through three generations: the Belgian–Luxembourg child study
J2  - Int J Obes Relat Metab Disord
PY  - 1995
VL  - 19
IS  - Suppl. 3
SP  - 5
EP  - 9
ER  - 
TY  - JOUR
LB  - 8.
AU  - Grio, R
AU  - Porpiglia, M
TI  - Obesity: internal medicine, obstetric and gynecological problems related to overweight
J2  - Panminerva Med
PY  - 1994
VL  - 36
SP  - 138
EP  - 141
ER  - 
TY  - JOUR
LB  - 9.
AU  - Parsons, TJ
AU  - Power, C
AU  - Logan, S
AU  - Summerbell, CD
TI  - Childhood predictors of adult obesity: a systematic review
J2  - Int J Obes Relat Metab Disord
PY  - 1999
VL  - 23
IS  - Suppl. 8
SP  - 1
EP  - 107
ER  - 
TY  - JOUR
LB  - 10.
AU  - Flegal, KM
AU  - Troiano, RP
AU  - Pamuk, ER
AU  - Kuczmarski, RJ
AU  - Campbell, SM
TI  - The influence of smoking cessation on the prevalence of overweight in the United States
J2  - N Engl J Med
PY  - 1995
VL  - 333
SP  - 1165
EP  - 1170
ER  - 
TY  - JOUR
LB  - 11.
AU  - Stewart, L
AU  - Van de Ven, L
AU  - Katsarou, V
AU  - Rentziou, E
AU  - Doran, M
AU  - Jackson, P
TI  - High prevalence of obesity in ambulatory children and adolescents with intellectual disability
J2  - J Intellect Disabil Res
PY  - 2009
VL  - 53
SP  - 882
EP  - 886
ER  - 
TY  - JOUR
LB  - 12.
AU  - Gale, L
AU  - Naqvi, H
AU  - Russ, L
TI  - Asthma, smoking and BMI in adults with intellectual disabilities: a community-based survey
J2  - J Intellect Disabil Res
PY  - 2009
VL  - 53
SP  - 787
EP  - 796
ER  - 
TY  - JOUR
LB  - 13.
AU  - Bhaumik, S
AU  - Watson, JM
AU  - Thorp, CF
AU  - Tyrer, F
AU  - McGrother, CW
TI  - Body mass index in adults with intellectual disability: distribution, associations and service implications: a population-based prevalence study
J2  - J Intellect Disabil Res
PY  - 2008
VL  - 52
SP  - 287
EP  - 298
ER  - 
TY  - BOOK
LB  - 14.
AU  - Vandenbroeck, IP
AU  - Goossens, J
AU  - Clemens, M
TI  - Building the obesity system map
CY  - Foresight tackling obesities
PB  - future choices
PY  - 2007
UR  - www.foresight.gov.uk
Y2  - January 2010
ER  - 
TY  - ELEC
LB  - 15.
AU  - Vandenbroeck, IP
AU  - Goossens, J
AU  - Clemens, M
TI  - Obesity system atlas. Foresight tackling obesities: future choices date
PY  - 2003
UR  - www.foresight.gov.uk
M1  - January 2010
ER  - 
TY  - JOUR
LB  - 16.
AU  - Gami, AS
AU  - Caples, SM
AU  - Somers, VK
TI  - Obesity and obstructive sleep apnea
J2  - Endocrinol Metab Clin North Am
PY  - 2003
VL  - 32
SP  - 869
EP  - 894
ER  - 
TY  - BOOK
LB  - 17.
AU  - Scarborough, P
AU  - Bhatnagar, P
AU  - Wickramasinghe, K
AU  - Smolina, K
AU  - Mitchell, C
AU  - Rayner, M
TI  - Coronary heart disease statistics 2010 edition
CY  - London
PB  - British Heart Foundation
PY  - 2010
ER  - 
TY  - JOUR
LB  - 18.
AU  - Kopelman, P
TI  - Health risks associated with overweight and obesity
J2  - Obes Rev
PY  - 2007
VL  - 8
IS  - Suppl. 1
SP  - 13
EP  - 17
ER  - 
TY  - JOUR
LB  - 19.
AU  - Wilson, PW
AU  - D’Agostino, RB
AU  - Sullivan, L
AU  - Parise, H
AU  - Kannel, WB
TI  - Overweight and obesity as determinants of cardiovascular risk: the Framingham experience
J2  - Arch Intern Med
PY  - 2002
VL  - 162
SP  - 1867
EP  - 1872
ER  - 
TY  - JOUR
LB  - 20.
AU  - Field, AE
AU  - Coakley, EH
AU  - Must, A
AU  - Spadano, JL
AU  - Laird, N
AU  - Dietz, WH
TI  - Impact of overweight on the risk of developing common chronic diseases during a 10-year period
J2  - Arch Intern Med
PY  - 2001
VL  - 161
SP  - 1581
EP  - 1586
ER  - 
TY  - JOUR
LB  - 21.
AU  - Li, KK
AU  - Kushida, C
AU  - Powell, NB
AU  - Riley, RW
AU  - Guilleminault, C
TI  - Obstructive sleep apnea syndrome: a comparison between Far-East Asian and white men
J2  - Laryngoscope
PY  - 2000
VL  - 110
SP  - 1689
EP  - 1693
ER  - 
TY  - JOUR
LB  - 22.
AU  - Ong, KC
AU  - Clerk, AA
TI  - Comparison of the severity of sleep-disordered breathing in Asian and Caucasian patients seen at a sleep disorders center
J2  - Respir Med
PY  - 1998
VL  - 92
SP  - 843
EP  - 848
ER  - 
TY  - RPRT
LB  - 23.
AU  - Controller and Auditor General
AU  - Bourn, J
TI  - Tackling obesity in England
CY  - London
PB  - Stationery Office
PY  - 2001
UR  - www%20nao.org%20uk/publications/nao_reports
Y2  - September 2010
ER  - 
TY  - JOUR
LB  - 24.
AU  - Calle, EE
AU  - Thun, MJ
AU  - Petrelli, JM
AU  - Rodriguez, C
AU  - Heath, CW, Jr.
TI  - Body-mass index and mortality in a prospective cohort of US adults
J2  - N Engl J Med
PY  - 1999
VL  - 341
SP  - 1097
EP  - 1105
ER  - 
TY  - JOUR
LB  - 25.
AU  - Bray, GA
TI  - Obesity: a time bomb to be defused
J2  - Lancet
PY  - 1998
VL  - 352
SP  - 160
EP  - 161
ER  - 
TY  - BOOK
LB  - 26.
AU  - Brown, TJ
TI  - Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children
PB  - National Institute for Health and Clinical Excellence
PY  - 2006
UR  - www.nice.org.uk/nicemedia/pdf/CG43NICEGuideline.pdf
ER  - 
TY  - JOUR
LB  - 27.
AU  - Lean, ME
AU  - Han, TS
AU  - Morrison, CE
TI  - Waist circumference as a measure for indicating need for weight management
J2  - BMJ
PY  - 1995
VL  - 311
SP  - 158
EP  - 161
ER  - 
TY  - JOUR
LB  - 28.
AU  - Barba, C
AU  - Cavalli-Sforza, T
AU  - Cutter, J
AU  - Darnton-Hill, I
AU  - Deurenberg, P
AU  - Deurenberg-Yap, M
TI  - Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies
J2  - Lancet
PY  - 2004
VL  - 363
SP  - 157
EP  - 163
ER  - 
TY  - JOUR
LB  - 29.
AU  - Dhaliwal, SS
AU  - Welborn, TA
TI  - Measurement error and ethnic comparisons of measures of abdominal obesity
J2  - Prev Med
PY  - 2009
VL  - 49
SP  - 148
EP  - 152
ER  - 
TY  - JOUR
LB  - 30.
AU  - Kumar, S
AU  - Hanif, W
AU  - Zaman, J
AU  - Sattar, N
AU  - Patel, K
AU  - Khunti, K
TI  - Lower thresholds for diagnosis and management of obesity in British South Asians
J2  - Int J Clin Pract
PY  - 2011
VL  - 64
SP  - 378
EP  - 379
ER  - 
TY  - ELEC
LB  - 31.
AU  - Dr Foster
UR  - www.drfosterhealth.co.uk/
M1  - September 2010
ER  - 
TY  - JOUR
LB  - 32.
AU  - Allender, S
AU  - Rayner, M
TI  - The burden of overweight and obesity-related ill health in the UK
J2  - Obes Rev
PY  - 2007
VL  - 8
SP  - 467
EP  - 473
ER  - 
TY  - JOUR
LB  - 33.
AU  - Royal College
TI  - Royal College of Physicians of Edinburgh Consensus Conference on Medical Management of Stroke, 26–27 May 1998
J2  - Age Ageing
PY  - 1998
VL  - 27
SP  - 665
EP  - 666
ER  - 
TY  - JOUR
LB  - 34.
AU  - Wadden, TA
AU  - Berkowitz, RI
AU  - Womble, LG
AU  - Sarwer, DB
AU  - Phelan, S
AU  - Cato, RK
TI  - Randomized trial of lifestyle modification and pharmacotherapy for obesity
J2  - N Engl J Med
PY  - 2005
VL  - 353
SP  - 2111
EP  - 2120
ER  - 
TY  - RPRT
LB  - 35.
AU  - House of Commons Health Committee
TI  - Obesity: third report of session 2003/04
CY  - London
PB  - HMSO
PY  - 2004
ER  - 
TY  - JOUR
LB  - 36.
AU  - Epstein, L
AU  - Ogden, J
TI  - A qualitative study of GPs’ views of treating obesity
J2  - Br J Gen Pract
PY  - 2005
VL  - 55
SP  - 750
EP  - 754
ER  - 
TY  - ELEC
LB  - 37.
AU  - Higgins, JPT
AU  - Green, S
TI  - Cochrane handbook for systematic reviews of interventions
UR  - www.cochrane-handbook.org/
M1  - January 2010
ER  - 
TY  - JOUR
LB  - 38.
AU  - O’Meara, S
AU  - Riemsma, R
AU  - Shirran, L
AU  - Mather, L
AU  - ter Riet, G
TI  - A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity
J2  - Health Technol Assess
PY  - 2001
VL  - 5
IS  - 18
ER  - 
TY  - JOUR
LB  - 39.
AU  - O’Meara, S
AU  - Riemsma, R
AU  - Shirran, L
AU  - Mather, L
AU  - ter Riet, G
TI  - The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment
J2  - Health Technol Assess
PY  - 2002
VL  - 6
IS  - 6
ER  - 
TY  - JOUR
LB  - 40.
AU  - Clegg, A
AU  - Colquitt, J
AU  - Sidhu, M
AU  - Royle, P
AU  - Walker, A
TI  - Clinical and cost effectiveness of surgery for morbid obesity: a systematic review and economic evaluation
J2  - Int J Obes
PY  - 2003
VL  - 27
SP  - 1167
EP  - 1177
ER  - 
TY  - JOUR
LB  - 41.
AU  - Burch, J
AU  - McKenna, C
AU  - Palmer, S
AU  - Norman, G
AU  - Glanville, J
AU  - Sculpher, M
TI  - Rimonabant for the treatment of overweight and obese people
J2  - Health Technol Assess
PY  - 2008
VL  - 13
IS  - Suppl. 3
SP  - 13
EP  - 22
ER  - 
TY  - ELEC
LB  - 42.
UR  - www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/53777708en.pdf
M1  - January 2010
ER  - 
TY  - ELEC
LB  - 43.
AU  - The NHS Health Checks Programme
UR  - www.healthcheck.nhs.uk/
M1  - January 2010
ER  - 
TY  - ELEC
LB  - 44.
AU  - European Medicines Agency
TI  - European Medicines Agency recommends suspension of marketing authorisation for sibutramine year 2010
UR  - www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Sibutramine_107/WC500094238.pdf
M1  - January 2010
ER  - 
TY  - GEN
LB  - 45.
AU  - British Medical Association and Royal Pharmaceutical Society of Great Britain
TI  - British national formulary
CY  - London
PB  - BMA and RPS
PY  - 2009
ER  - 
TY  - JOUR
LB  - 46.
AU  - Johansson, K
AU  - Neovius, K
AU  - DeSantis, SM
AU  - Rossner, S
AU  - Neovius, M
TI  - Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis
J2  - Obes Rev
PY  - 2009
VL  - 10
SP  - 564
EP  - 575
ER  - 
TY  - JOUR
LB  - 47.
AU  - Schulz, KF
AU  - Chalmers, I
AU  - Hayes, RJ
AU  - Altman, DG
TI  - Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
J2  - JAMA
PY  - 1995
VL  - 273
SP  - 408
EP  - 412
ER  - 
TY  - JOUR
LB  - 48.
AU  - Avenell, A
AU  - Broom, J
AU  - Brown, TJ
AU  - Poobalan, A
AU  - Aucott, L
AU  - Stearns, SC
TI  - Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement
J2  - Health Technol Assess
PY  - 2004
VL  - 8
IS  - 21
ER  - 
TY  - JOUR
LB  - 49.
AU  - Jadad, AR
AU  - Moore, RA
AU  - Carroll, D
AU  - Jenkinson, C
AU  - Reynolds, DJ
AU  - Gavaghan, DJ
TI  - Assessing the quality of reports of randomized clinical trials: is blinding necessary?
J2  - Control Clin Trials
PY  - 1996
VL  - 17
SP  - 1
EP  - 12
ER  - 
TY  - JOUR
LB  - 50.
AU  - Salanti, G
AU  - Higgins, JP
AU  - Ades, A
AU  - Ionnidis, JP
TI  - Evaluation of networks of randomized trials
J2  - Stat Methods Med Res
PY  - 2008
VL  - 17
SP  - 279
EP  - 301
ER  - 
TY  - BOOK
LB  - 51.
AU  - Spiegelhalter, DJ
AU  - Thomas, A
AU  - Best, NG
TI  - WinBUGS version 1.4 user manual
CY  - Cambridge
PB  - Cambridge MRC Biostatistics Unit
ER  - 
TY  - JOUR
LB  - 52.
AU  - Apfelbaum, M
AU  - Vague, P
AU  - Ziegler, O
AU  - Hanotin, C
AU  - Thomas, F
AU  - Leutenegger, E
TI  - Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine
J2  - Am J Med
PY  - 1999
VL  - 106
SP  - 179
EP  - 184
ER  - 
TY  - JOUR
LB  - 53.
AU  - Audikovszky, M
AU  - Pados, G
AU  - Seres, I
AU  - Harangi, M
AU  - Fulop, P
AU  - Katona, E
TI  - Orlistat increases serum paraoxonase activity in obese patients
J2  - Nutr Metab Cardiovasc Dis
PY  - 2007
VL  - 17
SP  - 268
EP  - 273
ER  - 
TY  - JOUR
LB  - 54.
AU  - Aydin, N
AU  - Topsever, P
AU  - Kaya, A
AU  - Karasakal, M
AU  - Duman, C
AU  - Dagar, A
TI  - Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients?
J2  - Tohoku J Exp Med
PY  - 2004
VL  - 202
SP  - 173
EP  - 180
ER  - 
TY  - JOUR
LB  - 55.
AU  - Bakris, G
AU  - Calhoun, D
AU  - Egan, B
AU  - Hellmann, C
AU  - Dolker, M
AU  - Kingma, I
TI  - Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension
J2  - J Hypertens
PY  - 2002
VL  - 20
SP  - 2257
EP  - 2267
ER  - 
TY  - JOUR
LB  - 56.
AU  - Beck-da-Silva, L
AU  - Higginson, L
AU  - Fraser, M
AU  - Williams, K
AU  - Haddad, H
AU  - Beck-da-Silva, L
TI  - Effect of orlistat in obese patients with heart failure: a pilot study
J2  - Congest Heart Fail
PY  - 2005
VL  - 11
SP  - 118
EP  - 123
ER  - 
TY  - JOUR
LB  - 57.
AU  - Berne, C
AU  - the Orlistat Swedish Type 2 Diabetes Study Group
TI  - A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin
J2  - Diabet Med
PY  - 2005
VL  - 22
SP  - 612
EP  - 618
ER  - 
TY  - JOUR
LB  - 58.
AU  - Bloch, KV
AU  - Salles, GF
AU  - Muxfeldt, ES
TI  - Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial
J2  - J Hypertens
PY  - 2003
VL  - 21
SP  - 2159
EP  - 2165
ER  - 
TY  - JOUR
LB  - 59.
AU  - Borges, RL
AU  - Ribeiro-Filho, FF
AU  - Carvalho, KM
AU  - Zanella, MT
AU  - Borges, RL
AU  - Ribeiro-Filho, FF
TI  - Impact of weight loss on adipocytokines, C-reactive protein and insulin sensitivity in hypertensive women with central obesity
J2  - Arq Bras Cardiol
PY  - 2007
VL  - 89
SP  - 409
EP  - 414
ER  - 
TY  - JOUR
LB  - 60.
AU  - Bray, GA
AU  - Blackburn, GL
AU  - Ferguson, JM
AU  - Greenway, FL
AU  - Jain, AK
AU  - Mendel, CM
TI  - Sibutramine produces dose-related weight loss
J2  - Obes Res
PY  - 1999
VL  - 7
SP  - 189
EP  - 198
ER  - 
TY  - JOUR
LB  - 61.
AU  - Broom, I
AU  - Hughes, E
AU  - Dodson, P
AU  - Reckless, J
AU  - on behalf of the Orlistat UK Study Group
TI  - The role of orlistat in the treatment of obese patients with mild to moderate hypercholesterolaemia: consequences for coronary risk
J2  - Br J Cardiol
PY  - 2002
VL  - 9
SP  - 460
EP  - 468
ER  - 
TY  - JOUR
LB  - 62.
AU  - Broom, I
AU  - Wilding, J
AU  - Stott, P
AU  - Myers, N
AU  - UK Multimorbidity Study Group
TI  - Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK multimorbidity study
J2  - Int J Clin Pract
PY  - 2002
VL  - 56
SP  - 494
EP  - 499
ER  - 
TY  - JOUR
LB  - 63.
AU  - Chou, KM
AU  - Huang, BY
AU  - Fanchiang, JK
AU  - Chen, CH
TI  - Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients
J2  - Chang Gung Med J
PY  - 2007
VL  - 30
SP  - 538
EP  - 546
ER  - 
TY  - JOUR
LB  - 64.
AU  - Cocco, G
AU  - Pandolfi, S
AU  - Rousson, V
TI  - Sufficient weight reduction decreases cardiovascular complications in diabetic patients with the metabolic syndrome: a randomized study of orlistat as an adjunct to lifestyle changes (diet and exercise)
J2  - Heart Drug
PY  - 2005
VL  - 5
SP  - 68
EP  - 74
ER  - 
TY  - JOUR
LB  - 65.
AU  - Cuellar, GE
AU  - Ruiz, AM
AU  - Monsalve, MC
AU  - Berber, A
TI  - Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population
J2  - Obes Res
PY  - 2000
VL  - 8
SP  - 71
EP  - 82
ER  - 
TY  - JOUR
LB  - 66.
AU  - Davidson, MH
AU  - Hauptman, J
AU  - DiGirolamo, M
AU  - Foreyt, JP
AU  - Halsted, CH
AU  - Heber, D
TI  - Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial
J2  - JAMA
PY  - 1999
VL  - 281
SP  - 235
EP  - 242
ER  - 
TY  - JOUR
LB  - 67.
AU  - Derosa, G
AU  - Mugellini, A
AU  - Ciccarelli, L
AU  - Fogari, R
AU  - Derosa, G
AU  - Mugellini, A
TI  - Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet
J2  - Clin Ther
PY  - 2003
VL  - 25
SP  - 1107
EP  - 1122
ER  - 
TY  - JOUR
LB  - 68.
AU  - Derosa, G
AU  - Cicero, AF
AU  - Murdolo, G
AU  - Ciccarelli, L
AU  - Fogari, R
AU  - Cicero, AFG
TI  - Comparison of metabolic effects of orlistat and sibutramine treatment in type 2 diabetic obese patients
J2  - Diabetes Nutr Metab
PY  - 2004
VL  - 17
SP  - 222
EP  - 229
ER  - 
TY  - JOUR
LB  - 69.
AU  - Derosa, G
AU  - Cicero, AF
AU  - Murdolo, G
AU  - Piccinni, MN
AU  - Fogari, E
AU  - Bertone, G
TI  - Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients
J2  - Diabetes Obes Metab
PY  - 2005
VL  - 7
SP  - 47
EP  - 55
ER  - 
TY  - JOUR
LB  - 70.
AU  - de Simone, G
AU  - Romano, C
AU  - De Caprio, C
AU  - Contaldo, F
AU  - Salanitri, T
AU  - di Luzio, PU
TI  - Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects
J2  - Nutr Metab Cardiovasc Dis
PY  - 2005
VL  - 15
SP  - 24
EP  - 30
ER  - 
TY  - JOUR
LB  - 71.
AU  - Despres, JP
AU  - Golay, A
AU  - Sjöström, L
AU  - Rimonabant in Obesity-Lipids Study Group
TI  - Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
J2  - N Engl J Med
PY  - 2005
VL  - 353
SP  - 2121
EP  - 2134
ER  - 
TY  - JOUR
LB  - 72.
AU  - Di Francesco, V
AU  - Sacco, T
AU  - Zamboni, M
AU  - Bissoli, L
AU  - Zoico, E
AU  - Mazzali, G
TI  - Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study
J2  - Ann Nutr Metab
PY  - 2007
VL  - 51
SP  - 75
EP  - 81
ER  - 
TY  - JOUR
LB  - 73.
AU  - Didangelos, TP
AU  - Thanopoulou, AK
AU  - Bousboulas, SH
AU  - Sambanis, CL
AU  - Athyros, VG
AU  - Spanou, EA
TI  - The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study
J2  - Curr Med Res Opin
PY  - 2004
VL  - 20
SP  - 1393
EP  - 1401
ER  - 
TY  - JOUR
LB  - 74.
AU  - Dixon, AN
AU  - Valsamakis, G
AU  - Hanif, MW
AU  - Field, A
AU  - Boutsiadis, A
AU  - Harte, A
TI  - Effect of the orlistat on serum endotoxin lipopolysaccharide and adipocytokines in South Asian individuals with impaired glucose tolerance
J2  - Int J Clin Pract
PY  - 2008
VL  - 62
SP  - 1124
EP  - 1129
ER  - 
TY  - JOUR
LB  - 75.
AU  - Drent, ML
AU  - Popp-Snijders, C
AU  - Ader, HJ
AU  - Jansen, JB
AU  - van der Veen, EA
TI  - Lipase inhibition and hormonal status, body composition and gastrointestinal processing of a liquid high-fat mixed meal in moderately obese subjects
J2  - Obes Res
PY  - 1995
VL  - 3
SP  - 573
EP  - 581
ER  - 
TY  - JOUR
LB  - 76.
AU  - Drent, ML
AU  - Larsson, I
AU  - William-Olsson, T
AU  - Quaade, F
AU  - Czubayko, F
AU  - von Bergmann, K
TI  - Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study
J2  - Int J Obes Rel Metab Disord
PY  - 1995
VL  - 19
SP  - 221
EP  - 226
ER  - 
TY  - JOUR
LB  - 77.
AU  - Erdmann, J
AU  - Lippl, F
AU  - Klose, G
AU  - Schusdziarra, V
TI  - Cholesterol lowering effect of dietary weight loss and orlistat treatment – efficacy and limitations
J2  - Aliment Pharmacol Ther
PY  - 2004
VL  - 19
SP  - 1173
EP  - 1179
ER  - 
TY  - JOUR
LB  - 78.
AU  - Erondu, N
AU  - Addy, C
AU  - Lu, K
AU  - Mallick, M
AU  - Musser, B
AU  - Gantz, I
TI  - NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine
J2  - Obesity
PY  - 2007
VL  - 15
SP  - 2027
EP  - 2042
ER  - 
TY  - JOUR
LB  - 79.
AU  - Fanghanel, G
AU  - Cortinas, L
AU  - Sanchez-Reyes, L
AU  - Berber, A
TI  - A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity
J2  - Int J Obes Rel Metab Disord
PY  - 2000
VL  - 24
SP  - 144
EP  - 150
ER  - 
TY  - JOUR
LB  - 80.
AU  - Fanghanel, G
AU  - Cortinas, L
AU  - Sanchez-Reyes, L
AU  - Gomez-Santos, R
AU  - Campos-Franco, E
AU  - Berber, A
TI  - Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension
J2  - Adv Ther
PY  - 2003
VL  - 20
SP  - 101
EP  - 113
ER  - 
TY  - JOUR
LB  - 81.
AU  - Faria, AN
AU  - Ribeiro Filho, FF
AU  - Kohlmann, NE
AU  - Gouvea, F, Sr
AU  - Zanella, MT
TI  - Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients
J2  - Diabetes Obes Metab
PY  - 2005
VL  - 7
SP  - 246
EP  - 253
ER  - 
TY  - JOUR
LB  - 82.
AU  - Finer, N
AU  - James, WP
AU  - Kopelman, PG
AU  - Lean, ME
AU  - Williams, G
TI  - One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor
J2  - Int J Obes Rel Metab Disord
PY  - 2000
VL  - 24
SP  - 306
EP  - 313
ER  - 
TY  - JOUR
LB  - 83.
AU  - Finer, N
AU  - Bloom, SR
AU  - Frost, GS
AU  - Banks, LM
AU  - Griffiths, J
TI  - Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study
J2  - Diabetes Obes Metab
PY  - 2000
VL  - 2
SP  - 105
EP  - 112
ER  - 
TY  - JOUR
LB  - 84.
AU  - Florakis, D
AU  - Diamanti-Kandarakis, E
AU  - Katsikis, I
AU  - Nassis, GP
AU  - Karkanaki, A
AU  - Georgopoulos, N
TI  - Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study
J2  - Int J Obes
PY  - 2008
VL  - 32
SP  - 692
EP  - 699
ER  - 
TY  - JOUR
LB  - 85.
AU  - Garcia, JM
AU  - Iyer, D
AU  - Poston, WS
AU  - Marcelli, M
AU  - Reeves, R
AU  - Foreyt, J
TI  - Rise of plasma ghrelin with weight loss is not sustained during weight maintenance
J2  - Obesity
PY  - 2006
VL  - 14
SP  - 1716
EP  - 1723
ER  - 
TY  - JOUR
LB  - 86.
AU  - Gokcel, A
AU  - Gumurdulu, Y
AU  - Karakose, H
AU  - Melek, EE
AU  - Tanaci, N
AU  - BascilTutuncu, N
TI  - Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity
J2  - Diabetes Obes Metab
PY  - 2002
VL  - 4
SP  - 49
EP  - 55
ER  - 
TY  - JOUR
LB  - 87.
AU  - Grudell, AB
AU  - Sweetser, S
AU  - Camilleri, M
AU  - Eckert, DJ
AU  - Vazquez-Roque, MI
AU  - Carlson, PJ
TI  - A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults
J2  - Gastroenterology
PY  - 2008
VL  - 135
SP  - 1142
EP  - 1154
ER  - 
TY  - JOUR
LB  - 88.
AU  - Guimaraes, C
AU  - Pereira, LR
AU  - Iucif, JN
AU  - Cesarino, EJ
AU  - de Almeida, CA
AU  - de Carvalho, D
TI  - Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients
J2  - Arq Brasil Endocrinol Metabol
PY  - 2006
VL  - 50
SP  - 1020
EP  - 1025
ER  - 
TY  - JOUR
LB  - 89.
AU  - Guy-Grand, B
AU  - Drouin, P
AU  - Eschwege, E
AU  - Gin, H
AU  - Joubert, JM
AU  - Valensi, P
TI  - Effects of orlistat on obesity-related diseases – a six-month randomized trial
J2  - Diabetes Obes Metab
PY  - 2004
VL  - 6
SP  - 375
EP  - 383
ER  - 
TY  - JOUR
LB  - 90.
AU  - Halpern, A
AU  - Leite, CC
AU  - Herszkowicz, N
AU  - Barbato, A
AU  - Costa, AP
AU  - Halpern, A
TI  - Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study
J2  - Rev Hosp Clin Fac Med São Paulo
PY  - 2002
VL  - 57
SP  - 98
EP  - 102
ER  - 
TY  - JOUR
LB  - 91.
AU  - Halpern, A
AU  - Mancini, MC
AU  - Suplicy, H
AU  - Zanella, MT
AU  - Repetto, G
AU  - Gross, J
TI  - Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients
J2  - Diabetes Obes Metab
PY  - 2003
VL  - 5
SP  - 180
EP  - 188
ER  - 
TY  - JOUR
LB  - 92.
AU  - Hanefeld, M
AU  - Sachse, G
TI  - The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial
J2  - Diabetes Obes Metab
PY  - 2002
VL  - 4
SP  - 415
EP  - 423
ER  - 
TY  - JOUR
LB  - 93.
AU  - Hanotin, C
AU  - Thomas, F
AU  - Jones, SP
AU  - Leutenegger, E
AU  - Drouin, P
TI  - Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study
J2  - Int J Obes Rel Metab Disord
PY  - 1998
VL  - 22
SP  - 32
EP  - 38
ER  - 
TY  - JOUR
LB  - 94.
AU  - Hauner, H
AU  - Meier, M
AU  - Wendland, G
AU  - Kurscheid, T
AU  - Lauterbach, K
AU  - Study, G
TI  - Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study
J2  - Exp Clin Endocrinol Diabetes
PY  - 2004
VL  - 112
SP  - 201
EP  - 207
ER  - 
TY  - JOUR
LB  - 95.
AU  - Hauptman, J
AU  - Lucas, C
AU  - Boldrin, MN
AU  - Collins, H
AU  - Segal, KR
TI  - Orlistat in the long-term treatment of obesity in primary care settings
J2  - Arch Fam Med
PY  - 2000
VL  - 9
SP  - 160
EP  - 167
ER  - 
TY  - JOUR
LB  - 96.
AU  - Hazenberg, BP
TI  - Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients
J2  - Cardiology
PY  - 2000
VL  - 94
SP  - 152
EP  - 158
ER  - 
TY  - JOUR
LB  - 97.
AU  - Hill, JO
AU  - Hauptman, J
AU  - Anderson, JW
AU  - Fujioka, K
AU  - O’Neil, PM
AU  - Smith, DK
TI  - Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study
J2  - Am J Clin Nutr
PY  - 1999
VL  - 69
SP  - 1108
EP  - 1116
ER  - 
TY  - JOUR
LB  - 98.
AU  - Hollander, PA
AU  - Elbein, SC
AU  - Hirsch, IB
AU  - Kelley, D
AU  - McGill, J
AU  - Taylor, T
TI  - Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study
J2  - Diabetes Care
PY  - 1998
VL  - 21
SP  - 1288
EP  - 1294
ER  - 
TY  - JOUR
LB  - 99.
AU  - Hung, YJ
AU  - Chen, YC
AU  - Pei, D
AU  - Kuo, SW
AU  - Hsieh, CH
AU  - Wu, LY
TI  - Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with type 2 diabetes
J2  - Diabetic Med
PY  - 2005
VL  - 22
SP  - 1024
EP  - 1030
ER  - 
TY  - JOUR
LB  - 100.
AU  - Kaya, A
AU  - Aydin, N
AU  - Topsever, P
AU  - Filiz, M
AU  - Ozturk, A
AU  - Dagar, A
TI  - Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients
J2  - Biomed Pharmacother
PY  - 2004
VL  - 58
SP  - 582
EP  - 587
ER  - 
TY  - JOUR
LB  - 101.
AU  - Kelley, DE
AU  - Bray, GA
AU  - Pi-Sunyer, FX
AU  - Klein, S
AU  - Hill, J
AU  - Miles, J
TI  - Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial
J2  - Diabetes Care
PY  - 2002
VL  - 25
SP  - 1033
EP  - 1041
ER  - 
TY  - JOUR
LB  - 102.
AU  - Kelley, DE
AU  - Kuller, LH
AU  - McKolanis, TM
AU  - Harper, P
AU  - Mancino, J
AU  - Kalhan, S
TI  - Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes
J2  - Diabetes Care
PY  - 2004
VL  - 27
SP  - 33
EP  - 40
ER  - 
TY  - JOUR
LB  - 103.
AU  - Kiortsis, DN
AU  - Tsouli, S
AU  - Filippatos, TD
AU  - Konitsiotis, S
AU  - Elisaf, MS
TI  - Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study
J2  - Nutr Metab Cardiovasc Dis
PY  - 2008
VL  - 18
SP  - 207
EP  - 210
ER  - 
TY  - JOUR
LB  - 104.
AU  - Krempf, M
AU  - Louvet, JP
AU  - Allanic, H
AU  - Miloradovich, T
AU  - Joubert, JM
AU  - Attali, JR
TI  - Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity
J2  - Int J Obes Rel Metab Disord
PY  - 2003
VL  - 27
SP  - 591
EP  - 597
ER  - 
TY  - JOUR
LB  - 105.
AU  - Kuo, C
AU  - Pei, D
AU  - Yao, C
AU  - Hsieh, M
AU  - Kuo, S
TI  - Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study
J2  - Int J Clin Pract
PY  - 2006
VL  - 60
SP  - 906
EP  - 910
ER  - 
TY  - JOUR
LB  - 106.
AU  - Lindgarde, F
TI  - The effect of orlistat body weight and coronary heart disease risk profile in obese patients: the Swedish multimorbidity study
J2  - J Intern Med
PY  - 2000
VL  - 248
SP  - 245
EP  - 254
ER  - 
TY  - JOUR
LB  - 107.
AU  - Lindholm, A
AU  - Bixo, M
AU  - Bjorn, I
AU  - Wolner-Hanssen, P
AU  - Eliasson, M
AU  - Larsson, A
TI  - Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial
J2  - Fertil Steril
PY  - 2008
VL  - 89
SP  - 1221
EP  - 1228
ER  - 
TY  - JOUR
LB  - 108.
AU  - Mathus-Vliegen, EM
AU  - van Ierland-van Leeuwen, ML
AU  - Bennink, RJ
TI  - Influences of fat restriction and lipase inhibition on gastric emptying in obesity
J2  - Int J Obes
PY  - 2006
VL  - 30
SP  - 1203
EP  - 1210
ER  - 
TY  - JOUR
LB  - 109.
AU  - McNulty, SJ
AU  - Ur, E
AU  - Williams, G
AU  - Multicenter Sibutramine Study Group
TI  - A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin
J2  - Diabetes Care
PY  - 2003
VL  - 26
SP  - 125
EP  - 131
ER  - 
TY  - JOUR
LB  - 110.
AU  - Miles, JM
AU  - Leiter, L
AU  - Hollander, P
AU  - Wadden, T
AU  - Anderson, JW
AU  - Doyle, M
TI  - Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin
J2  - Diabetes Care
PY  - 2002
VL  - 25
SP  - 1123
EP  - 1128
ER  - 
TY  - JOUR
LB  - 111.
AU  - Muls, E
AU  - Kolanowski, J
AU  - Scheen, A
AU  - Van Gaal, L
AU  - ObelHyx Study Group
TI  - The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study
J2  - Int J Obes
PY  - 2001
VL  - 25
SP  - 1713
EP  - 1721
ER  - 
TY  - JOUR
LB  - 112.
AU  - Ozcelik, O
AU  - Dogan, H
AU  - Kelestimur, H
TI  - Effects of a weight-reduction program with orlistat on serim leptin levels in obese women: a 12-week, randomized, placebo-controlled study
J2  - Curr Ther Res
PY  - 2004
VL  - 65
SP  - 127
EP  - 137
ER  - 
TY  - JOUR
LB  - 113.
AU  - Ozcelik, O
AU  - Dogan, H
AU  - Celik, H
AU  - Ayar, A
AU  - Serhatlioglu, S
AU  - Kelestimur, H
TI  - Effects of different weight loss protocols on serum leptin levels in obese females
J2  - Physiol Res
PY  - 2005
VL  - 54
SP  - 271
EP  - 277
ER  - 
TY  - JOUR
LB  - 114.
AU  - Pathan, MF
AU  - Latif, ZA
AU  - Nazneen, NE
AU  - Mili, SU
TI  - Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience
J2  - Bangladesh Med Res Counc Bull
PY  - 2004
VL  - 30
SP  - 1
EP  - 8
ER  - 
TY  - JOUR
LB  - 115.
AU  - Pi-Sunyer, FX
AU  - Aronne L, J
AU  - Heshmati, HM
AU  - Devin, J
AU  - Rosenstock, J
TI  - Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients – RIO-North America: a randomized controlled trial
J2  - JAMA
PY  - 2006
VL  - 295
SP  - 761
EP  - 775
ER  - 
TY  - JOUR
LB  - 116.
AU  - Porter, JA
AU  - Raebel, M A
AU  - Conner, DA
AU  - Lanty, FA
AU  - Vogel, EA
AU  - Gay, EC
TI  - The long-term outcomes of sibutramine effectiveness on weight (LOSE weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization
J2  - Am J Manag Care
PY  - 2004
VL  - 10
SP  - 369
EP  - 376
ER  - 
TY  - JOUR
LB  - 117.
AU  - Poston, WS
AU  - Reeves, RS
AU  - Haddock, CK
AU  - Stormer, S
AU  - Balasubramanyam, A
AU  - Satterwhite, O
TI  - Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification
J2  - Int J Obes
PY  - 2003
VL  - 27
SP  - 1486
EP  - 1493
ER  - 
TY  - JOUR
LB  - 118.
AU  - Poston, WS
AU  - Haddock, CK
AU  - Pinkston, MM
AU  - Pace, P
AU  - Reeves, RS
AU  - Karakoc, N
TI  - Evaluation of a primary care-oriented brief counselling intervention for obesity with and without orlistat
J2  - J Intern Med
PY  - 2006
VL  - 260
SP  - 388
EP  - 398
ER  - 
TY  - JOUR
LB  - 119.
AU  - Redmon, JB
AU  - Raatz, SK
AU  - Reck, KP
AU  - Swanson, JE
AU  - Kwong, CA
AU  - Fan, Q
TI  - One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial
J2  - Diabetes Care
PY  - 2003
VL  - 26
SP  - 2505
EP  - 2511
ER  - 
TY  - JOUR
LB  - 120.
AU  - Rossner, S
AU  - Sjostrom, L
AU  - Noack, R
AU  - Meinders, AE
AU  - Noseda, G
TI  - Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group
J2  - Obes Res
PY  - 2000
VL  - 8
SP  - 49
EP  - 61
ER  - 
TY  - JOUR
LB  - 121.
AU  - Sarac, F
AU  - Pehlivan, M
AU  - Celebi, G
AU  - Saygili, F
AU  - Yilmaz, C
AU  - Kabalak, T
TI  - Effects of sibutramine on thermogenesis in obese patients assessed via immersion calorimetry
J2  - Adv Ther
PY  - 2006
VL  - 23
SP  - 1016
EP  - 1029
ER  - 
TY  - JOUR
LB  - 122.
AU  - Sari, R
AU  - Balci, MK
AU  - Cakir, M
AU  - Altunbas, H
AU  - Karayalcin, U
AU  - Sari, R
TI  - Comparison of efficacy of sibutramine or orlistat versus their combination in obese women
J2  - Endocr Res
PY  - 2004
VL  - 30
SP  - 159
EP  - 167
ER  - 
TY  - JOUR
LB  - 123.
AU  - Sari, R
AU  - Balci, MK
AU  - Coban, E
AU  - Yazicioglu, G
TI  - Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women
J2  - Int J Obes Rel Metab Disord
PY  - 2004
VL  - 28
SP  - 1059
EP  - 1063
ER  - 
TY  - JOUR
LB  - 124.
AU  - Sathyapalan, T
AU  - Cho, LW
AU  - Kilpatrick, ES
AU  - Coady, AM
AU  - Atkin, SL
TI  - A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study
J2  - Clin Endocrinol
PY  - 2008
VL  - 69
SP  - 931
EP  - 935
ER  - 
TY  - JOUR
LB  - 125.
AU  - Scheen, AJ
AU  - Finer, N
AU  - Hollander, P
AU  - Jensen, MD
AU  - Van Gaal, LFR
AU  - IO-Diabetes Study Group
TI  - Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
J2  - Lancet
PY  - 2006
VL  - 368
SP  - 1660
EP  - 1672
ER  - 
TY  - JOUR
LB  - 126.
AU  - Scholze, J
AU  - Grimm, E
AU  - Herrmann, D
AU  - Unger, T
AU  - Kintscher, U
TI  - Optimal treatment of obesity-related hypertension: the hypertension–obesity–sibutramine (HOS) study
J2  - Circulation
PY  - 2007
VL  - 115
SP  - 1991
EP  - 1998
ER  - 
TY  - JOUR
LB  - 127.
AU  - Serrano-Rios, M
AU  - Melchionda, N
AU  - Moreno-Carretero, E
AU  - Spanish Investigators
TI  - Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy
J2  - Diabet Med
PY  - 2002
VL  - 19
SP  - 119
EP  - 124
ER  - 
TY  - JOUR
LB  - 128.
AU  - Shechter, M
AU  - Beigel, R
AU  - Freimark, D
AU  - Matetzky, S
AU  - Feinberg, MS
TI  - Short-term sibutramine therapy is associated with weight loss and improved endothelial function in obese patients with coronary artery disease
J2  - Am J Cardiol
PY  - 2006
VL  - 97
SP  - 1650
EP  - 1653
ER  - 
TY  - JOUR
LB  - 129.
AU  - Shi, YF
AU  - Pan, CY
AU  - Hill, J
AU  - Gao, Y
TI  - Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed type 2 diabetes
J2  - Diabet Med
PY  - 2005
VL  - 22
SP  - 1737
EP  - 1743
ER  - 
TY  - JOUR
LB  - 130.
AU  - Smith, IG
AU  - Goulder, MA
AU  - Sibutramine, Clinical Study Group
TI  - Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity
J2  - J Fam Pract
PY  - 2001
VL  - 50
SP  - 505
EP  - 512
ER  - 
TY  - JOUR
LB  - 131.
AU  - Swinburn, BA
AU  - Carey, D
AU  - Hills, AP
AU  - Hooper, M
AU  - Marks, S
AU  - Proietto, J
TI  - Effect of orlistat on cardiovascular disease risk in obese adults
J2  - Diabetes Obes Metab
PY  - 2005
VL  - 7
SP  - 254
EP  - 262
ER  - 
TY  - JOUR
LB  - 132.
AU  - Tambascia, MA
AU  - Geloneze, B
AU  - Repetto, EM
AU  - Geloneze, SR
AU  - Picolo, M
AU  - Magro, DO
TI  - Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial
J2  - Diabetes Obes Metab
PY  - 2003
VL  - 5
SP  - 338
EP  - 344
ER  - 
TY  - JOUR
LB  - 133.
AU  - Tankova, T
AU  - Dakovska, G
AU  - Lazarova, M
AU  - Dakovska, L
AU  - Kirilov, G
AU  - Koev, D
TI  - Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects
J2  - Acta Diabetol
PY  - 2004
VL  - 41
SP  - 146
EP  - 153
ER  - 
TY  - JOUR
LB  - 134.
AU  - Tiikkainen, M
AU  - Bergholm, R
AU  - Rissanen, A
AU  - Aro, A
AU  - Salminen, I
AU  - Tamminen, M
TI  - Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women
J2  - Am J Clin Nutr
PY  - 2004
VL  - 79
SP  - 22
EP  - 30
ER  - 
TY  - JOUR
LB  - 135.
AU  - Torgerson, JS
AU  - Hauptman, J
AU  - Boldrin, MN
AU  - Sjostrom, L
AU  - Torgerson, JS
AU  - Hauptman, J
TI  - XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients
J2  - Diabetes Care
PY  - 2004
VL  - 27
SP  - 155
EP  - 161
ER  - 
TY  - JOUR
LB  - 136.
AU  - Turker, I
AU  - Demirag, NG
AU  - Tanaci, N
AU  - Tutar, NU
AU  - Kirbas, I
TI  - Effects of orlistat plus diet on postprandial lipemia and brachial artery reactivity in normolipidemic, obese women with normal glucose tolerance: a prospective, randomized, controlled study
J2  - Curr Ther Res
PY  - 2006
VL  - 67
SP  - 159
EP  - 173
ER  - 
TY  - JOUR
LB  - 137.
AU  - Van Gaal, LFB
TI  - Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study
J2  - Eur J Clin Pharmacol
PY  - 1998
VL  - 54
SP  - 125
EP  - 132
ER  - 
TY  - JOUR
LB  - 138.
AU  - Van Gaal, LF
AU  - Rissanen, AM
AU  - Scheen, AJ
AU  - Ziegler, O
AU  - Rössner, S
TI  - Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
J2  - Lancet
PY  - 2005
VL  - 365
SP  - 1389
EP  - 1397
ER  - 
TY  - JOUR
LB  - 139.
AU  - Vazquez Roque, MI
AU  - Camilleri, M
AU  - Clark, MM
AU  - Tepoel, DA
AU  - Jensen, MD
AU  - Graszer, KM
TI  - Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine
J2  - Clin Gastroenterol Hepatol
PY  - 2007
VL  - 5
SP  - 829
EP  - 837
ER  - 
TY  - JOUR
LB  - 140.
AU  - Walsh, KM
AU  - Leen, E
AU  - Lean, ME
TI  - The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females
J2  - Int J Obes Rel Metab Disord
PY  - 1999
VL  - 23
SP  - 1009
EP  - 1015
ER  - 
TY  - JOUR
LB  - 141.
AU  - Wang, T
AU  - Pei, D
AU  - Li, J
AU  - Tsai, W
AU  - Tsai, C
AU  - Yao, C
TI  - Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study
J2  - Int J Clin Pract
PY  - 2005
VL  - 59
SP  - 746
EP  - 750
ER  - 
TY  - JOUR
LB  - 142.
AU  - Wirth, AK
AU  - Krause, J
TI  - Long-term weight loss with sibutramine: a randomized controlled trial
J2  - JAMA
PY  - 2001
VL  - 286
SP  - 1331
EP  - 1339
ER  - 
TY  - JOUR
LB  - 143.
AU  - Wirth, A
AU  - Scholze, J
AU  - Sharma, AM
AU  - Matiba, B
AU  - Boenner, G
TI  - Reduced left ventricular mass after treatment of obese patients with sibutramine: an echocardiographic multicentre study
J2  - Diabetes Obes Metab
PY  - 2006
VL  - 8
SP  - 674
EP  - 681
ER  - 
TY  - JOUR
LB  - 144.
AU  - Zannad, F
AU  - Gille, B
AU  - Grentzinger, A
AU  - Bruntz, JF
AU  - Hammadi, M
AU  - Boivin, JM
TI  - Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction
J2  - Am Heart J
PY  - 2002
VL  - 144
SP  - 508
EP  - 515
ER  - 
TY  - JOUR
LB  - 145.
AU  - Kolberg, JA
AU  - Jorgensen, T
AU  - Gerwien, RW
AU  - Hamren, S
AU  - McKenna, MP
AU  - Moler, E
TI  - Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort
J2  - Diabetes Care
PY  - 2009
VL  - 32
SP  - 1207
EP  - 1212
ER  - 
TY  - JOUR
LB  - 146.
AU  - Cox, BD
AU  - Wichelow, MJ
AU  - Prevost, AT
TI  - The development of cardiovascular disease in relation to anthropometric indices and hypertension in British adults
J2  - Int J Obes
PY  - 1998
VL  - 22
SP  - 966
EP  - 973
ER  - 
TY  - JOUR
LB  - 147.
AU  - Meigs, JB
AU  - Wilson, PWF
AU  - Fox, CS
AU  - Vasan, RS
AU  - Nathan, DM
AU  - Sullivan, LM
TI  - Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease
J2  - J Clin Endocrinol Metab
PY  - 2006
VL  - 91
SP  - 2906
EP  - 2912
ER  - 
TY  - JOUR
LB  - 148.
AU  - Bogers, RP
AU  - Bemelmans, WJE
AU  - Hoogenveen, RT
AU  - Boshuizen, HC
AU  - Woodward, M
AU  - Knekt, P
TI  - Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels – a meta-analysis of 21 cohort studies including more than 300,000 persons
J2  - Arch Intern Med
PY  - 2007
VL  - 167
SP  - 1720
EP  - 1728
ER  - 
TY  - JOUR
LB  - 149.
AU  - Delaney, JS
AU  - Daskalopoulou, SS
AU  - Brophy, JM
AU  - Steele, RJ
AU  - Opatrny, L
AU  - Suissa, S
TI  - Lifestyle variables and the risk of myocardial infarction in the general practice research database
J2  - BMC Cardiovasc Disord
PY  - 2007
VL  - 18
SP  - 7
EP  - 38
ER  - 
TY  - JOUR
LB  - 150.
AU  - Whitlock, G
AU  - Lewington, S
AU  - Sherliker, P
AU  - Clarke, R
AU  - Emberson, J
AU  - Halsey, J
TI  - Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
J2  - Lancet
PY  - 2009
VL  - 373
SP  - 1083
EP  - 1096
ER  - 
TY  - JOUR
LB  - 151.
AU  - Song, YQ
AU  - Manson, JE
AU  - Meigs, JB
AU  - Ridker, PM
AU  - Buring, JE
AU  - Liu, SM
TI  - Comparison of usefulness of body mass index versus metabolic risk factors in predicting 10-year risk of cardiovascular events in women
J2  - Am J Cardiol
PY  - 2007
VL  - 100
SP  - 1654
EP  - 1658
ER  - 
TY  - ELEC
LB  - 152.
AU  - GPRD
TI  - General Practice Research Database
PY  - 2011
UR  - www.gprd.com
M1  - January 2011
ER  - 
TY  - JOUR
LB  - 153.
AU  - Chrisholm, J
TI  - The READ clinical classification
J2  - BMJ
PY  - 1990
VL  - 300
SP  - 1092
EP  - 1096
ER  - 
TY  - JOUR
LB  - 154.
AU  - de Gonzalez, AB
AU  - Hartge, P
AU  - Cerhan, JR
AU  - Flint, AJ
AU  - Hannan, L
AU  - MacInnis, RJ
TI  - Body-mass index and mortality among 1.46 million white adults
J2  - N Engl J Med
PY  - 2010
VL  - 363
SP  - 2211
EP  - 2219
ER  - 
TY  - JOUR
LB  - 155.
AU  - Lambert, PC
AU  - Royston, P
TI  - Further development of flexible parametric models for survival analysis
J2  - Stata J
PY  - 2009
VL  - 9
SP  - 265
EP  - 290
ER  - 
TY  - JOUR
LB  - 156.
AU  - Durrelman, S
AU  - Simon, R
TI  - Flexible regression-models with cubic-splines
J2  - Stat Med
PY  - 1989
VL  - 8
SP  - 551
EP  - 561
ER  - 
TY  - JOUR
LB  - 157.
AU  - Ara, R
AU  - Brennan, A
TI  - The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four Western countries
J2  - Obes Rev
PY  - 2007
VL  - 8
SP  - 363
EP  - 371
ER  - 
TY  - JOUR
LB  - 158.
AU  - Brennan, A
AU  - Ara, R
AU  - Sterz, R
AU  - Matiba, B
AU  - Bergemann, R
TI  - Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany
J2  - Eur J Health Econ
PY  - 2006
VL  - 7
SP  - 276
EP  - 284
ER  - 
TY  - JOUR
LB  - 159.
AU  - Caro, JJ
AU  - Stillman, IO
AU  - Danel, A
AU  - Getsios, D
AU  - McEwan, P
TI  - Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model
J2  - J Med Econ
PY  - 2007
VL  - 10
SP  - 239
EP  - 254
ER  - 
TY  - JOUR
LB  - 160.
AU  - Foxcroft, DR
TI  - Orlistat for the treatment of obesity: cost utility model
J2  - Obes Rev
PY  - 2005
VL  - 6
SP  - 323
EP  - 328
ER  - 
TY  - JOUR
LB  - 161.
AU  - Hertzman, P
TI  - The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden: a treatment responder approach
J2  - Pharmacoeconomics
PY  - 2005
VL  - 23
SP  - 1007
EP  - 1020
ER  - 
TY  - JOUR
LB  - 162.
AU  - Iannazzo, S
AU  - Zaniolo, O
AU  - Pradelli, L
TI  - Economic evaluation of treatment with orlistat in Italian obese patients
J2  - Curr Med Res Opin
PY  - 2008
VL  - 24
SP  - 63
EP  - 74
ER  - 
TY  - JOUR
LB  - 163.
AU  - Lacey, LA
AU  - Wolf, A
AU  - O’Shea, D
AU  - Erny, S
AU  - Ruof, J
TI  - Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland
J2  - Int J Obes
PY  - 2005
VL  - 29
SP  - 975
EP  - 982
ER  - 
TY  - JOUR
LB  - 164.
AU  - Lamotte, M
AU  - Annemans, L
AU  - Lefever, A
AU  - Nechelput, M
AU  - Masure, J
TI  - A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients
J2  - Diabetes Care
PY  - 2002
VL  - 25
SP  - 303
EP  - 308
ER  - 
TY  - JOUR
LB  - 165.
AU  - Ruof, J
AU  - Golay, A
AU  - Berne, C
AU  - Collin, C
AU  - Lentz, J
AU  - Maetzel, A
TI  - Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland
J2  - Int J Obes
PY  - 2005
VL  - 29
SP  - 517
EP  - 523
ER  - 
TY  - JOUR
LB  - 166.
AU  - van Baal, PH
AU  - Hoeymans, N
AU  - Hoogenveen, RT
AU  - de Wit, GA
AU  - Westert, GP
TI  - Disability weights for comorbidity and their influence on health-adjusted life expectancy
J2  - Popul Health Metr
PY  - 2006
VL  - 4
SP  - 1
EP  - 7
ER  - 
TY  - JOUR
LB  - 167.
AU  - Warren, E
AU  - Brennan, A
AU  - Akehurst, R
TI  - Cost-effectiveness of sibutramine in the treatment of obesity
J2  - Med Decis Making
PY  - 2004
VL  - 24
SP  - 9
EP  - 19
ER  - 
TY  - JOUR
LB  - 168.
AU  - Hampp, C
AU  - Hartzema, AG
AU  - Kauf, TL
TI  - Cost-utility analysis of rimonabant in the treatment of obesity
J2  - Value Health
PY  - 2008
VL  - 11
SP  - 389
EP  - 399
ER  - 
TY  - JOUR
LB  - 169.
AU  - Roux, L
AU  - Kuntz, KM
AU  - Donaldson, C
AU  - Goldie, SJ
TI  - Economic evaluation of weight loss interventions in overweight and obese women
J2  - Obesity
PY  - 2006
VL  - 14
SP  - 1093
EP  - 1106
ER  - 
TY  - JOUR
LB  - 170.
AU  - Maetzel, A
AU  - Rouf, J
AU  - Covington, M
AU  - Wolf, A
TI  - Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus
J2  - Pharmacoeconomics
PY  - 2003
VL  - 21
SP  - 501
EP  - 512
ER  - 
TY  - JOUR
LB  - 171.
AU  - Macdonald, SM
AU  - Reeder, BA
AU  - Chen, Y
AU  - Despres, JP
TI  - Obesity in Canada: a descriptive analysis. Canadian Heart Health Surveys Research Group
J2  - CMAJ
PY  - 1997
VL  - 157
IS  - Suppl. 1
SP  - 3
EP  - 9
ER  - 
TY  - JOUR
LB  - 172.
AU  - Heitman, BL
AU  - Garby, L
TI  - Patterns of long-term weight changes in overweight developing Danish men and women aged between 30 and 60 years
J2  - Int J Obes
PY  - 1999
VL  - 23
SP  - 1074
EP  - 1078
ER  - 
TY  - JOUR
LB  - 173.
AU  - James, WP
AU  - Astrup, A
AU  - Finer, N
AU  - Hilsted, J
AU  - Kopelman, P
AU  - Rossner, S
TI  - Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance
J2  - Lancet
PY  - 2000
VL  - 356
SP  - 2119
EP  - 2125
ER  - 
TY  - JOUR
LB  - 174.
AU  - Wirth, A
TI  - Sustained weight reduction after cessation of obesity treatment with sibutramine
J2  - Dtsch Med Wochenschr
PY  - 2004
VL  - 129
SP  - 1002
EP  - 1005
ER  - 
TY  - JOUR
LB  - 175.
AU  - Oster, G
AU  - Thompson, D
AU  - Edelsberg, J
AU  - Bird, AP
AU  - Colditz, GA
TI  - Lifetime health and economic benefits of weight loss among obese persons
J2  - Am J Public Health
PY  - 1999
VL  - 89
SP  - 1536
EP  - 1542
ER  - 
TY  - JOUR
LB  - 176.
AU  - Ward, S
AU  - Jones, ML
AU  - Pandor, A
AU  - Holmes, M
AU  - Ara, R
AU  - Ryan, A
TI  - A systematic review and economic evaluation of statins for the prevention of coronary events
J2  - Health Technol Assess
PY  - 2007
VL  - 11
IS  - 14
ER  - 
TY  - JOUR
LB  - 177.
AU  - Earnshaw, J
AU  - Lewis, G
TI  - NICE guide to the methods of technology appraisal – pharmaceutical industry perspective
J2  - Pharmacoeconomics
PY  - 2008
VL  - 26
SP  - 725
EP  - 727
ER  - 
TY  - JOUR
LB  - 178.
AU  - Kind, P
AU  - Dolan, P
AU  - Gudex, C
AU  - Williams, A
TI  - Variations in population health status: results from a United Kingdom national questionnaire survey
J2  - BMJ
PY  - 1998
VL  - 316
SP  - 736
EP  - 741
ER  - 
TY  - GEN
LB  - 179.
AU  - Department of Health
TI  - Health survey for England 1998: cardiovascular disease
CY  - London
PB  - Department of Health
PY  - 1998
ER  - 
TY  - ELEC
LB  - 180.
AU  - Hernández Alava, M
AU  - Wailoo, AJ
AU  - Ara, R
TI  - Tails from the Peak District: adjusted censored mixture models of EQ-5D health state utility values
UR  - http://eprints%20whiterose%20ac%20uk/
M1  - 1 October 2010
ER  - 
TY  - JOUR
LB  - 181.
AU  - Curtis, L
AU  - Netten, A
J2  - Unit costs of health and social care
PY  - 2007
ER  - 
TY  - JOUR
LB  - 182.
AU  - Youman, P
AU  - Wilson, K
AU  - Harraf, F
AU  - Kalra, L
TI  - The economic burden of stroke in the United Kingdom
J2  - Pharmacoeconomics
PY  - 2003
VL  - 21
IS  - Suppl. 1
SP  - 43
EP  - 50
ER  - 
TY  - JOUR
LB  - 183.
AU  - Ara, R
AU  - Pandor, A
AU  - Stevens, J
AU  - Rees, A
AU  - Rafia, R
TI  - Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation Introduction
J2  - Health Technol Assess
PY  - 2009
VL  - 13
IS  - 34
ER  - 
TY  - JOUR
LB  - 184.
AU  - Clarke, P
AU  - Gray, A
TI  - Estimating utility values for health states of type 2 diabetes patients using the EQ-5D(UKPDS 62)
J2  - Med Decis Making
PY  - 2002
VL  - 22
SP  - 340
EP  - 349
ER  - 
TY  - JOUR
LB  - 185.
AU  - Gillett, M
AU  - Dallosso, HM
AU  - Dixon, S
AU  - Brennan, A
AU  - Carey, ME
AU  - Campbell, MJ
TI  - Cost effectiveness of the DESMOND structured education programme for patients newly diagnosed with type 2 diabetes
J2  - Diabetologia
PY  - 2009
VL  - 52
SP  - S12
ER  - 
TY  - BOOK
LB  - 186.
AU  - Scarborough, P
AU  - Bhatnagar, P
AU  - Wickramasinghe, K
AU  - Smolina, K
AU  - Mitchell, C
AU  - Rayner, M
TI  - Coronary heart disease statistics 2010 edition
CY  - London
PB  - British Heart Foundation
PY  - 2010
ER  - 
TY  - JOUR
LB  - 187.
AU  - Juni, P
AU  - Holenstein, F
AU  - Sterne, J
AU  - Bartlett, C
AU  - Egger, M
TI  - Direction and impact of language bias in meta analysis of controlled tirlas, empirical study
J2  - Int J Epidemiol
PY  - 2002
VL  - 31
SP  - 115
EP  - 123
ER  - 
TY  - JOUR
LB  - 188.
AU  - James, WP
AU  - Caterson, ID
AU  - Coutinho, W
AU  - Finer, N
AU  - Van Gaal, LF
AU  - Maggioni, AP
TI  - Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects
J2  - N Engl J Med
PY  - 2010
VL  - 363
SP  - 905
EP  - 917
ER  - 
TY  - JOUR
LB  - 189.
AU  - Anderson, KM
AU  - Wilson, PWF
AU  - Odell, PM
AU  - Kannel, WB
TI  - An updated coronary risk profile: a statement for health professionals
J2  - Circulation
PY  - 1991
VL  - 83
SP  - 356
EP  - 362
ER  - 
TY  - JOUR
LB  - 190.
AU  - D’Agostino, RB
AU  - Russell, MW
AU  - Huse, DM
AU  - Ellison, RC
AU  - Silbershatz, H
AU  - Wilson, PWF
TI  - Primary and subsequent coronary risk appraisal: new results from the Framingham Study
J2  - Am Heart J
PY  - 2000
VL  - 139
SP  - 272
EP  - 281
ER  - 
TY  - JOUR
LB  - 191.
AU  - Ibrahim, JG
AU  - Chu, HT
AU  - Chen, LM
TI  - Basic concepts and methods for joint models of longitudinal and survival data
J2  - J Clin Oncol
PY  - 2010
VL  - 28
SP  - 2796
EP  - 2801
ER  - 
TY  - JOUR
LB  - 192.
AU  - Herrett, E
AU  - Thomas, SL
AU  - Schoonen, WM
AU  - Smeeth, L
AU  - Hall, AJ
TI  - Validation and validity of diagnoses in the General Practice Research Database: a systematic review
J2  - Br J Clin Pharmacol
PY  - 2010
VL  - 69
SP  - 4
EP  - 14
ER  - 
TY  - JOUR
LB  - 193.
AU  - Dias, S
AU  - Welton, NJ
AU  - Caldwell, DM
AU  - Ades, AE
TI  - Checking consistency in mixed treatment comparison meta-analysis
J2  - Stat Med
PY  - 2010
VL  - 29
SP  - 932
EP  - 944
ER  - 
TY  - JOUR
LB  - 194.
AU  - Patschan, SS
TI  - Obesity-related hypertension
J2  - Cardiol Rev
PY  - 2007
VL  - 24
SP  - 32
EP  - 35
ER  - 
TY  - JOUR
LB  - 195.
AU  - Anderson, KM
AU  - Odell, PM
AU  - Wilson, PWF
TI  - Cardiovascular disease risk profiles
J2  - Am Heart J
PY  - 1990
VL  - 121
SP  - 293
EP  - 298
ER  - 
TY  - JOUR
LB  - 196.
AU  - Clarke, PM
AU  - Gray, AM
AU  - Briggs, A
AU  - Farmer, AJ
AU  - Fenn, P
AU  - Stevens, RJ
TI  - A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)
J2  - Diabetologia
PY  - 2004
VL  - 47
SP  - 1747
EP  - 1759
ER  - 
TY  - JOUR
LB  - 197.
AU  - Stratton, IM
AU  - Adler, AI
AU  - Neil, HA
AU  - Matthews, DR
AU  - Manley, SE
AU  - Cull, CA
TI  - Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
J2  - BMJ
PY  - 2000
VL  - 321
SP  - 405
EP  - 412
ER  - 
TY  - CHAP
LB  - 198.
AU  - Downey, W
AU  - Beck, P
AU  - McNutt, M
AU  - Stang, MR
AU  - Osei, W
AU  - Nichol, J
TI  - Health databases in Saskatchewan
A2  - Strom, BL
T2  - Pharmacoepidemiology
CY  - Chichester
PB  - Wiley
PY  - 2000
SP  - 325
EP  - 345
ER  - 
TY  - JOUR
LB  - 199.
AU  - Caro, JJ
AU  - Ishak, K
AU  - Migliaccio-Walle, K
TI  - Estimating survival for cost effectiveness analyses: a case study in atherothrombosis
J2  - Value Health
PY  - 2004
VL  - 7
SP  - 627
EP  - 635
ER  - 
TY  - JOUR
LB  - 200.
AU  - Caro, JJ
AU  - Migliaccio-Walle, K
TI  - Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Apirin in Patients at Risk of Ischaemic Events
J2  - J Med
PY  - 1999
VL  - 107
SP  - 568
EP  - 572
ER  - 
TY  - JOUR
LB  - 201.
AU  - Colditz, GA
AU  - Walter, MBBS
AU  - Willcott, C
TI  - Weight gain as a risk factor for clinical diabetes mellitus in women
J2  - Ann Intern Med
PY  - 1995
VL  - 122
SP  - 481
EP  - 486
ER  - 
TY  - JOUR
LB  - 202.
AU  - Sjostrom, CD
AU  - Lissner, L
AU  - Wedel, H
AU  - Sjostrom, L
TI  - Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study
J2  - Obes Res
PY  - 1999
VL  - 7
SP  - 477
EP  - 484
ER  - 
TY  - JOUR
LB  - 203.
AU  - Gorsky, RD
AU  - Pamuk, E
AU  - Williamson, DF
AU  - Shaffer, PA
AU  - Koplan, JP
TI  - The 25-year health care costs of women who remain overweight after 40 years of age
J2  - Am J Prev Med
PY  - 1996
VL  - 12
SP  - 388
EP  - 394
ER  - 
TY  - JOUR
LB  - 204.
AU  - Gregg, EW
AU  - Cadwell, BL
AU  - Cheng, YJ
AU  - Cowie, CC
AU  - Williams, DE
AU  - Geiss, L
TI  - Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the US
J2  - Diabetes Care
PY  - 2004
VL  - 27
SP  - 2806
EP  - 2812
ER  - 
TY  - JOUR
LB  - 205.
AU  - Wannamethee, SG
AU  - Shaper, AG
AU  - Walker, M
TI  - Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes
J2  - J Epidemiol Community Health
PY  - 2005
VL  - 59
SP  - 134
EP  - 139
ER  - 
TY  - JOUR
LB  - 206.
AU  - Hu, FB
AU  - Manson, JE
AU  - Stampfer, MJ
AU  - Colditz, G
AU  - Liu, S
AU  - Solomon, CG
TI  - Diet, lifestyle, and the risk of type 2 diabetes mellitus in women
J2  - N Engl J Med
PY  - 2001
VL  - 345
SP  - 790
EP  - 797
ER  - 
TY  - JOUR
LB  - 207.
AU  - Lalonde, L
AU  - Clarke, AE
AU  - Joseph, L
AU  - Mackenzie, T
AU  - Grover, SA
TI  - Health-related quality of life with coronary heart disease prevention and treatment
J2  - J Clin Epidemiol
PY  - 2001
VL  - 54
SP  - 1011
EP  - 1018
ER  - 
TY  - JOUR
LB  - 208.
AU  - Currie, CJ
AU  - Morgan, C
AU  - Dixon, S
TI  - The financial costs of hospital care for people with diabetes who have single and multiple macrovascular complications
J2  - Diabetes Res Clin Pract
PY  - 2005
VL  - 67
SP  - 144
EP  - 151
ER  - 
TY  - JOUR
LB  - 209.
AU  - Hakim, Z
AU  - Wolf, A
AU  - Garrison, L
TI  - Estimating the effect of changes in body mass index on health state preferences
J2  - Pharmacoeconomics
PY  - 2002
VL  - 20
SP  - 393
EP  - 404
ER  - 
TY  - JOUR
LB  - 210.
AU  - Engel, SG
AU  - Crosby, RD
AU  - Kolotkin, RL
AU  - Hartley, GG
AU  - Williams, GR
AU  - Wonderlich, SA
TI  - Impact of weight loss and regain on quality of life: mirror image or differential effect?
J2  - Obes Res
PY  - 2003
VL  - 11
SP  - 1207
EP  - 1213
ER  - 
TY  - JOUR
LB  - 211.
AU  - Fryback, DG
AU  - Dasbach, EJ
AU  - Klein, R
AU  - Klein, BE
AU  - Dorn, N
AU  - Peterson, K
TI  - The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors
J2  - Med Decis Making
PY  - 1993
VL  - 13
SP  - 89
EP  - 102
ER  - 
TY  - JOUR
LB  - 212.
AU  - Mark, DB
AU  - Hlatky, MA
AU  - Califf, RM
AU  - Naylor, CD
AU  - Lee, KL
AU  - Armstrong, PW
TI  - Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction
J2  - N Engl J Med
PY  - 1995
VL  - 332
SP  - 1418
EP  - 1424
ER  - 
TY  - JOUR
LB  - 213.
AU  - Hiatt, MD
TI  - Thrombolytic therapy with streptokinase and tissue plasminogen activator in a patient with suspected acute myocardial infarction: a decision analysis
J2  - Cardiology
PY  - 1999
VL  - 91
SP  - 243
EP  - 249
ER  - 
TY  - JOUR
LB  - 214.
AU  - Sullivan, SD
AU  - Lew, DP
AU  - Devine, EB
AU  - Hakim, Z
AU  - Reiber, GE
AU  - Veenstra, DL
TI  - Health state preference assessment in diabetic peripheral neuropathy
J2  - Pharmacoeconomics
PY  - 2002
VL  - 20
SP  - 1079
EP  - 1089
ER  - 
TY  - JOUR
LB  - 215.
AU  - Churchill, DN
AU  - Torrance, GW
AU  - Taylor, DW
AU  - Barnes, CC
AU  - Ludwin, D
AU  - Shimizu, A
TI  - Measurement of quality of life in end-stage renal disease: the time trade-off approach
J2  - Clin Invest Med
PY  - 1987
VL  - 10
SP  - 14
EP  - 20
ER  - 
TY  - JOUR
LB  - 216.
AU  - Melse, JM
AU  - Essink-Bot, ML
AU  - Kramers, PG
AU  - Hoeymans, N
TI  - A national burden of disease calculation: Dutch disability-adjusted life-years. Dutch Burden of Disease Group
J2  - Am J Public Health
PY  - 2000
VL  - 90
SP  - 1241
EP  - 1247
ER  - 
TY  - JOUR
LB  - 217.
AU  - Kuntz, KM
AU  - Tsevat, J
AU  - Goldman, L
AU  - Weinstein, MC
TI  - Cost-effectiveness of routine coronary angiography after acute myocardial infarction
J2  - Circulation
PY  - 1996
VL  - 94
SP  - 957
EP  - 965
ER  -